trial

D-serine AudRem: R33 Phase

NCTId NCT05046353
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Suspended
Enrollment 60 (estimated)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2027-04-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Suspended
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-12-01
Primary completion
2027-04-01
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
D-serine

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
Nathan Kline Institute for Psychiatric ResearchCollaborator
National Institute of Mental Health (NIMH)Collaborator

Sites

1 total
New York, United States

Linked catalysts

1
D-serine AudRem: R33 Phase — primary completion2027-04-01

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE1,PHASE2
Primary Completion Date
2027-04-01
Status
SUSPENDED
relationships
The graph out of here
drug
D-serine
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
Nathan Kline Institute for Psychiatric Research
company
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizo Affective Disorder
indication
Schizophrenia
indication